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Insulin resistance first develops in the heart
1 well before 
its onset in other peripheral organs including the skel-
etal muscle. Cardiac insulin resistance is defined as the 
reduced ability of myocytes to increase glucose uptake in 
response to insulin stimulation.2 It is of importance because 
it reduces tolerance against ischemia–reperfusion injury and 
increases infarct size due to the loss of metabolic flexibility 
and endothelial dysfunction.3 Insulin resistance is accompa-
nied by significant morbidity and mortality, independent of 
other established risk factors. Even in the absence of hyper-
glycemia or overt diabetes, insulin resistance is closely 
associated with coronary artery disease,4 congestive heart 
failure,5 atherosclerosis, and cerebral stroke.6
Diprivan® (AstraZeneca Inc., Mississauga, ON, Canada), 
a fat emulsion-based propofol formulation, was recently 
shown to promote insulin resistance.7 It increased insulin 
levels but did not change blood glucose concentrations, 
resulting in a markedly reduced quantitative insulin sensi-
tivity check index, an index of insulin sensitivity.7 However, 
from that observation, it is unclear whether propofol or its 
solvent Intralipid® is causally involved in the generation 
of insulin resistance. In clinical practice, fat emulsions are 
commonly used as solvents to administer lipophilic drugs 
such as propofol or to provide IV nutrition to patients.8 
Even short IV infusions of fat emulsions were previously 
reported to impair insulin sensitivity (which determines 
whole body glucose disposal) in healthy nondiabetic vol-
unteers,9 but the effects of Intralipid on cardiac insulin resis-
tance are unknown. In this study, we sought to determine 
whether propofol, or its solvent Intralipid, alters glucose 
utilization in healthy and type-2 diabetic hearts and, if so, 
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how insulin signaling would be affected by these treat-
ments. Specifically, we hypothesized that both propofol and 
Intralipid would increase insulin resistance in the already 
metabolically compromised diabetic heart. To address this 
aim, we compared the effects of the 2 commercially avail-
able drugs Diprivan and Intralipid. The use of the work-
ing rat heart model allowed us to conduct the experiments 
under well-controlled conditions, independent of multiple 
confounding factors resulting from alterations in whole 
body physiology. For our experiments, we used hearts 
from fructose-fed rats, a well-established model of type-2 
diabetes with hyperglycemia, hyperinsulinemia, hypertri-
glyceridemia, insulin resistance, arterial hypertension, and 
abdominal obesity, consistent with all features of the human 
metabolic syndrome.10,11 Moreover, fructose-induced 
dietary diabetes resembles early type-2 diabetes,12 which is 
potentially reversible and devoid of the severe maladaptive 
consequences typically accompanying genetic or inbred 
models of diabetes mellitus.
METHODS
The investigation conforms to the Guide for the Care and 
Use of Laboratory Animals published by the U.S. National 
Institutes of Health (NIH Publication No. 85-23, revised 
1996), and the experimental protocol used in this investi-
gation was approved by the University of Alberta Animal 
Policy and Welfare Committee. All materials were from 
Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
Model of Type-2 Diabetes Mellitus Using 
Fructose Feeding
Male Sprague-Dawley rats (8 weeks of age, from the 
Biosciences breeding colony, University of Alberta, 
Edmonton, Canada) were fed for 6 weeks with standard 
chow (PicoLab® Laboratory Rodent diet 5LOD, LabDiet Inc., 
St. Louis, MO) and fructose (10% w/v) dissolved in drinking 
water and compared with untreated rats fed a fructose-free 
diet. The lipogenic sugar fructose, as opposed to glucose, 
feeds directly into the pool of C2-bodies in the liver caus-
ing increased hepatic triglyceride formation, followed by 
hyperlipidemia and insulin resistance. After only 6 weeks 
of fructose feeding, rats consistently exhibit the classical 
characteristics of type-2 diabetes including hyperglycemia, 
hyperinsulinemia, hypertriglyceridemia, insulin resistance, 
arterial hypertension, and abdominal obesity. This type-2 
diabetes model has been characterized in detail.11–13
Working Heart Perfusion Protocols
Rats (14 weeks) were anesthetized with pentobarbital (150 
mg·kg−1, intraperitoneally). Each heart was rapidly removed 
and perfused initially in a nonworking Langendorff mode 
with Krebs-Henseleit solution containing 3% bovine serum 
albumin for 10 minutes, before establishing the working 
mode perfusion as previously described.14 Left ventricular 
work (mL·min−1·mm Hg) was calculated as left ventricular 
work · cardiac output × (aortic systolic pressure − preload). 
Measurements of mechanical function were averaged for the 
initial 30 minutes of aerobic perfusion (no insulin) and for the 
following 60 minutes of perfusion in the presence of insulin. 
Hearts were assigned to the following 6 groups (Supplemental 
Digital Content 1, which is a scheme detailing the protocols, 
http://links.lww.com/AA/B32). Groups 1 and 2: untreated 
healthy or diabetic hearts perfused without insulin for 30 
minutes followed by 60 minutes with insulin; groups 3 and 
4: healthy or diabetic hearts perfused without insulin for 30 
minutes and then treated with insulin plus 10 μM propofol 
(Diprivan); and groups 5 and 6 (solvent controls): healthy or 
diabetic hearts perfused without insulin for 30 minutes and 
then treated with insulin plus Intralipid (25 μM, as corre-
sponding solvent control of Diprivan). Ten micromolar propo-
fol (Diprivan) was chosen because this concentration reflects 
the effect-site concentration at which loss of consciousness 
occurs in humans.15 Because the heart perfusate contained 3% 
bovine serum albumin, some of the administered propofol was 
likely bound, thereby reducing the free active concentration as 
occurs under clinical conditions. Additional healthy and dia-
betic hearts were perfused for 90 minutes without insulin or 
for 30 minutes only in the absence of insulin (required for the 
measurement of glucose uptake).
Metabolic Flux Measurements of Glycolysis
The rate of glycolysis was determined by perfusing hearts 
with [5-3H]glucose.16 Total myocardial 3H2O production 
(liberated from [5-3H]glucose at the enolase step of glycoly-
sis) was determined every 10 minutes and the rates were 
expressed as μmol·gdw−1·min−1.
Determination of Tissue Glycogen Content and 
[5-3H]glucose Incorporation
Glycogen content (μmol glucosyl units per gdw) and the 
incorporation of [5-3H]glucose into glycogen were also 
determined for each heart.14,16
Glucose Uptake in Perfused Working Hearts
Glucose uptake (in μmol·gdw−1·min−1) was calculated based 
on its metabolism by glycolysis and its incorporation into 
glycogen. The average rate of glucose uptake in the 30 to 90 
minutes treatment period is the sum of the rate of glycoly-
sis and the rate of glycogen synthesis. Glycogen synthesis 
in the 30 to 90 minutes treatment period is calculated from 
the increase in radiolabeled glycogen content (calculated as 
the difference between radiolabeled contents at 30 and 90 
minutes).
Citrate Synthase Activity (Oxidative Capacity)
The activity of the mitochondrial matrix marker enzyme 
citrate synthase was measured at 412 nm by monitoring the 
formation of thionitrobenzoate, as previously described.17
Determination of Glycolytic Metabolites
Heart tissue (75 mg) was deproteinized with perchloric acid 
and supernatants were adjusted to pH 3.5 using K2CO3 (5 
M). Glucose-6-phosphate, fructose-6-phosphate, and fruc-
tose-1,6-bisphosphate contents in heart tissue (nmol·gdw−1) 
were determined by a coupled enzymatic assay, as described 
previously.18
Immunoblotting
Total tissue homogenates were prepared from frozen heart 
tissue homogenized in ice-cold buffer containing 50 mM 
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Tris (pH 8.0), 150 mM NaCl, and 1% Nonidet P-40, supple-
mented with protease and phosphatase inhibitors, as previ-
ously described.14 Membrane and cytosolic fractions were 
prepared according to the methods reported by Lizotte et al.19 
Protein concentration was measured by Bradford assay. 
Densitometric analysis of immunoblots was performed using 
ImageJ software.a The following proteins were probed with 
the appropriate antibodies from Cell Signaling Technology 
(unless otherwise stated; Cell Signaling Technology, Inc., 
Danvers, MA): phospho-Akt (Ser473 and Thr308), Akt, 
phospho-GSK3β (Ser9), GSK3β, phospho-AMPK (Thr172), 
AMPK, phospho-ERK1/2 (Thr202/Tyr204), Erk1/2, phos-
pho-p38MAPK (Thr180/Tyr182), p38MAPK, phospho-JNK 
(Thr183/Tyr185; Millipore, Billerica, MA), JNK (Millipore), 
phospho-S6K1 (Thr389; Abcam, Cambridge, MA), S6K1 
(Abcam), insulin receptor substrate-1 (IRS-1), phospho-IRS-1 
(Ser1100/h1101, Ser307/h312), phospho-IRS-1 (Tyr608/h612; 
Abcam), GLUT4, protein kinase Cθ (PKCθ), and protein 
kinase CβII (PKCβII) (Santa Cruz Biotechnology, Dallas, TX). 
Because PKCβII persistently translocates to the membrane 
under insulin stimulation,20 it was measured in membrane 
fractions. Tubulin (Santa Cruz Biotechnology, Santa Cruz, 
CA) was used as loading control in blots where total tissue 
extracts or cytosolic fractions were used. GLUT4, PKCθ, 
and PKCβII were normalized to the membrane marker Na+/
K+-ATPase, which showed no difference in the expression 
between healthy and type-2 diabetic rat hearts (not shown). 
Immunoblots for the treatment groups (insulin, insulin plus 
Diprivan, and insulin plus Intralipid) were run within the 
same gel for each model (healthy or diabetic hearts). Samples 
of the same healthy and diabetic hearts with insulin treatment 
only were further run on additional gels to gauge the relative 
intensity levels of each protein of interest to allow direct com-
parisons between models.
Mass Spectrometry for Acylcarnitine Profiling of 
Cardiac Tissue
Tissue levels of 32 acylcarnitine species were measured 
using electrospray ionization tandem mass spectrometry, as 
described previously.14
Mass Spectrometry for the Determination of 
Phospholipids in Cardiac Tissue
Liquid chromatography-tandem mass spectrometry com-
bining high-performance liquid chromatography separa-
tion on normal-phase column with multiple parent-ion or 
neutral loss scans on a triple-quadruple mass spectrometer 
was used to analyze the following phospholipid classes from 
lipid extracts of cardiac tissues.21 The following species were 
determined: sphingomyelin, phosphatidylcholine, phos-
phatidylglycerol, phosphatidylethanolamine, phosphatidic 
acid, and ceramides. Supplemental Digital Content 2 con-
tains detailed protocols (http://links.lww.com/AA/B33).
Mass Spectrometry for the Determination of 
Sphingoid Bases in Cardiac Tissue
The profile of backbone sphingoid bases was determined 
after hydrolysis, as previously described (Supplemental 
Digital Content 2, http://links.lww.com/AA/B33).22 The 
sphingoid bases analyzed included C16-sphingosine, 
C16-sphinganine, C17-sphingosine, C18-sphingosine, 
C18-sphinganine, C20-sphingosine, C18-sphingadiene, 
deoxysphinganine, and deoxysphingosine. Software tools 
for quantitative analysis of mass spectrometric lipidome 
data were used.23
Statistical Analysis
Values are given as mean (SD) or median (25th, 75th per-
centile) depending on the underlying data distribution 
for the indicated number of independent observations. A 
sample size of 5 for changes in glucose uptake was calcu-
lated based on published data on insulin-induced cardiac 
glucose uptake.24,25 With an expected difference of 1.5 μmol 
glucose·gdw−1·min−1, an SD of 0.6 μmol glucose·gdw−1·min−1, 
an α level of 0.05, and a power of 0.8, a minimal sample size of 
5 was calculated. Additional hearts were enrolled to account 
for the intrinsic reduced insulin responsiveness of the dia-
betic heart. The significance of differences in hemodynamic 
and metabolic (glycolysis rates) variables among groups was 
determined by 2-way repeated-measures analysis of vari-
ance (ANOVA) followed by an all pairwise multiple com-
parison procedure using the Holm-Sidak method for post 
hoc analysis. Differences were evaluated by Student t test 
(2 groups) or by ANOVA followed by an all pairwise mul-
tiple comparison procedure using the Holm-Sidak method 
for post hoc analysis. Nonparametric methods (Kruskal-
Wallis ANOVA on ranks) were used in the case where the 
conditions for parametric ANOVA were not met (i.e., equal 
variance and normally distributed residuals). Normality 
was assessed using the Shapiro-Wilk test, whereas equal 
variance was assessed using the Levene test (the default P 
value of 0.05 to reject was used in both cases). Differences 
are considered significant if the overall P <0.05. SigmaPlot 
(version 12.0; Systat Software, Inc., Chicago, IL) was used 
for the analyses.
RESULTS
After 6 weeks of fructose feeding, rats exhibited total body 
insulin resistance. Glucose tolerance tests showed delayed 
glucose clearance with markedly increased blood glucose 
levels compared with healthy rats (Supplemental Digital 
Content 3, which shows glucose tolerance and insulin sensi-
tivity tests, http://links.lww.com/AA/B34). An intraperi-
toneal insulin challenge resulted in a less prominent blood 
glucose reduction in the fructose-fed diabetic rats compared 
with that in healthy rats (Supplemental Digital Content 
3, http://links.lww.com/AA/B34). We have previously 
shown that these rats also show increased fasting glucose, 
triglyceride, and insulin blood levels, the classical features 
of type-2 diabetes mellitus.11 Furthermore, during work-
ing mode perfusion, the hearts of diabetic rats exhibited a 
reduced insulin-stimulated glucose uptake rate (1.4 ± 0.6 
vs 2.4 ± 0.4 μmol·gdw−1·min−1; P = 0.002) (Fig. 1A), consis-
tent with cardiac insulin resistance. Diabetic hearts also had 
higher levels of triglycerides, lysophosphatidylcholine, and 
lysophosphatidylethanolamine and lower mitochondrial 
content and dysfunctional β-oxidation with increased tissue 
concentrations of acylcarnitines compared with hearts from 
age-matched healthy rats (Table 1).aAvailable at: http://rsbweb.nih.gov/ij/. Accessed December 1, 2008.
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Diprivan and Intralipid Reduce Glucose Uptake 
and Redirect Glucose to Glycogen Stores in 
Insulin-Stimulated Type-2 Diabetic Hearts
To evaluate the effects of Diprivan and Intralipid on the 
insulin response, Diprivan and Intralipid were added to 
the perfusate 3 minutes before insulin administration. In 
accordance with previous reports in rat hearts,26,27 insulin 
administration was accompanied with mild negative ino-
tropic effects (Table 2). Intralipid reduced glucose uptake in 
both healthy and diabetic hearts by 25% and 61% of insu-
lin response on average, respectively (Fig. 1A). Likewise, 
Diprivan reduced glucose uptake to a greater extent in both 
healthy and diabetic hearts by 48% and 109% of the insulin 
response, respectively (Fig. 1A). The reduced glucose uptake 
in Diprivan-treated healthy hearts and Diprivan-treated and 
Intralipid-treated diabetic hearts was due to a reduction in 
glycolytic flux rates (Fig. 1B). In insulin-stimulated healthy 
hearts, the treatment with both fat emulsions decreased total 
glycogen content (Fig. 1C), with the most profound effect 
occurring in the Intralipid group (h-INS versus h-INS/IL post 
hoc; P = 0.008). Conversely, glycogen levels increased in dia-
betic hearts (Fig. 1C), again with the largest effect occurring 
in the Intralipid group (ff-INS versus ff-INS/IL post hoc; 
P = 0.043). Consistent with reduced oxidative capacity in 
diabetic hearts, as measured by citrate synthase activity 
(Table 1), glucose was diverted from substrate oxidation to 
glycogen storage when exposed to fat emulsions. Together, 
these data show that Diprivan and Intralipid promote insu-
lin resistance, predominantly in diabetic hearts.
Diprivan and Intralipid Impair GLUT4 Trafficking 
in Insulin-Stimulated Type-2 Diabetic Hearts and 
Propofol Specifically Increases Phosphorylation 
of IRS-1 at Ser1100
GLUT4 protein content was reduced in insulin-stimulated 
diabetic hearts (Panel A in Supplemental Digital Content 4, 
which shows differences in protein expression and phos-
phorylation of insulin-stimulated healthy and diabetic 
hearts, http://links.lww.com/AA/B35), but membrane 
translocation was largely maintained (data not shown). 
When comparing the effect of Diprivan and Intralipid on 
GLUT4 trafficking to the sarcolemma in the healthy hearts, 
there was a clear propofol-specific impairment (Fig.  2A). 
GLUT4 translocation to the membrane was also reduced 
Figure 1. Glucose uptake, glycolysis, and glyco-
gen metabolism. A, Glucose uptake was calcu-
lated from glycolytic flux and glycogen synthesis 
over 60 minutes in all groups. B, Average rates 
of glycolysis without insulin (first 30 minutes) and 
with insulin (subsequent 60 minutes, hatched 
bars). Horizontal brackets indicate significant 
differences for factor “time.” C, Total and radio-
labeled (hatched bars) glycogen tissue content 
at the end of perfusions. gdw = gram dry heart 
weight; h = healthy; ff = fructose-fed; noINS = per-
fusion without insulin; INS = insulin alone; INS/
DIPR = perfusion with insulin and treated with 
Diprivan (10 μM); INS/IL = perfusion with insulin 
treated with Intralipid (25 μM); ANOVA = analysis 
of variance. N = 6–10 for each group. *Versus 
corresponding noINS group. #Versus correspond-
ing INS group.
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in Diprivan-treated and Intralipid-treated diabetic hearts 
(Fig. 2A). This was consistent with reduced glycolysis and 
glucose uptake, as measured with the radioactive tracer in 
the respective groups. The analysis of the glycolytic metab-
olites further revealed that only Diprivan reduced phospho-
fructokinase-1 activity in diabetic but not in healthy hearts 
(Supplemental Digital Content 5, a table showing glycolytic 
metabolites, http://links.lww.com/AA/B36). In terms of 
IRS-1 phosphorylation at Ser1100(h1101), there was also an 
evident propofol-specific effect in both healthy and diabetic 
hearts (Fig. 2B). Phosphorylation of IRS-1 at Ser307(h312) 
was already increased in diabetic hearts independent of 
any treatment (Fig. 2C, and Panel B in Supplemental Digital 
Content, http://links.lww.com/AA/B35). Phosphorylation 
of Tyr608(h612) of IRS-1 was similar between healthy and 
diabetic hearts and not affected by either treatments 
(Fig. 2D). There was no difference in the expression of IRS-1 
between healthy and diabetic hearts (data not shown). 
Overall, propofol impairs GLUT4 trafficking and specifi-
cally increases serine phosphorylation of IRS-1. Intralipid 
impairs GLUT4 trafficking only in type-2 diabetic hearts.
Diprivan and Intralipid Elicit a Distinct Activity 
Pattern of Metabolic and Stress Kinases in 
Insulin-Stimulated Type-2 Diabetic Hearts
By comparing the pattern of metabolic kinase phosphory-
lation between Diprivan and Intralipid treatment in insu-
lin-stimulated healthy hearts, we observed that propofol 
specifically increased Akt phosphorylation at Ser473 and 
Thr308 (Fig. 3, A and B). Diprivan and Intralipid similarly 
enhanced GSK3β phosphorylation (Fig. 3C), but neither 
treatment had any effect on AMPK phosphorylation (Fig. 
3D) nor any of the stress kinases tested (Fig. 4). However, in 
diabetic hearts, neither Diprivan nor Intralipid affected Akt 
phosphorylation at Ser473 or Thr308. GSK3β and AMPK 
phosphorylation were similarly enhanced by both Diprivan 
Table 1.  Characteristics of Healthy and Diabetic Hearts
H ff P Mean difference (CI)
Citrate synthase activity (μmol mL−1 min−1 μg−1) 20.2 (2.1) 16.9 (3.1) <0.001 3.3 (2.2–4.5)
Cardiac tissue triglycerides (μmol gdw−1) 6.35 (2.01) 7.74 (2.29) 0.016 −1.39 (−2.52 to −0.27)
Cardiac tissue levels of phospholipids
  Lysophosphatidylcholine (nmol mg−1) 151 (18) 198 (19) 0.019 −48 (−83 to −12)
  Lysophosphatidylethanolamine (nmol mg−1) 129 (27) 197 (27) 0.012 −68 (−115 to −21)
  Phosphatidylethanolamine (nmol mg−1) 50 (8) 66 (14) 0.119 −16 (−36 to 6)
  Sphingomyelin (nmol mg−1) 34.7 (6.8) 33.1 (8.5) 0.780 1.6 (−11.7 to 14.9)
Cardiac tissue levels of sphingolipids
  C16-sphingosine (pmol per 100 μg) 0.56 (0.14) 0.53 (0.08) 0.737 0.03 (−0.17 to 0.22)
  C18-sphingosine (pmol per 100 μg) 154 (21) 152 (29) 0.917 2 (−42 to 46)
  C18-sphinganine (pmol per 100 μg) 1.7 (0.3) 1.4 (0.2) 0.075 0.3 (−0.05 to 0.77)
  C18-sphingadiene (pmol per 100 μg) 41 (11) 40 (9) 0.924 1 (−17 to 18)
  C20-sphingosine (pmol per 100 μg) 0.35 (0.10) 0.50 (0.08) 0.057 −0.15 (−0.31 to 0.006)
Cardiac tissue levels of acylcarnitines
  Free carnitine (C0; nmol g−1) 441 (38) 492 (71) 0.207 −51 (−139 to 36)
  Total acylcarnitines (nmol g−1) 393 (86) 557 (44) 0.011 −164 (−276 to −51)
  Acetylcarnitine (C2; nmol g−1) 351 (86) 491 (30) 0.018 −140 (−247 to −32)
  Short-chain acylcarnitines (nmol g−1) 359 (86) 502 (32) 0.017 −143 (−252 to −34)
  Medium-chain acylcarnitines (nmol g−1) 0.97 (0.09) 1.42 (0.46) 0.070 −0.45 (−0.94 to 0.05)
  Long-chain acylcarnitines (nmol g−1) 33 (4) 53 (14) 0.016 −20 (−35 to −5)
Data are presented as mean (SD). Acylcarnitine tissue levels are presented as total acylcarnitines, short-chain (C2–C6), medium-chain (C8–C12), and long-chain 
(C14 and higher) acylcarnitines. N = 44 (citrate synthase activity); N = 30 (tissue triglycerides); and N = 5–6 (sphingolipids/acylcarnitines).
CI = confidence interval; ff = rats fed standard chow and 10% fructose added to the drinking water for 6 weeks; gdw = gram dry heart weight; h = age-matched 
healthy control rats (fed standard chow and water).
Table 2.  Cardiac Function in Perfused Healthy and Diabetic Hearts
h-noINS h-INS h-INS/DIPR h-INS/IL ff-noINS ff-INS ff-INS/DIPR ff-INS/IL
HR (min−1) Equilibration 241 (24) 262 (19) 256 (23) 252 (12) 229 (11) 228 (10) 232 (27) 229 (17)
Treatment 251 (28) 264 (17) 252 (34) 245 (13) 230 (15) 224 (16) 230 (22) 234 (10)
RM-ANOVA P (group);  
P (time); P (interaction)
0.36; 0.87; 0.12 0.92; 0.93; 0.22
CO (mL•min−1) Equilibration 66 (8) 67 (6) 65 (6) 69 (7) 65 (4) 67 (9) 66 (11) 63 (11)
Treatment 66 (7) 61 (9)a 66 (8) 65 (6)a 61 (6) 58 (13)a 64 (11) 62 (14)
RM-ANOVA P (group);  
P (time); P (interaction)
0.86; 0.004; 0.023 0.95; 0.010; 0.06
LVW (mm Hg•L min−1) Equilibration 7.95 (1.20) 7.97 (1.06) 7.92 (0.79) 8.19 (1.30) 8.19 (1.34) 8.36 (1.42) 8.58 (1.65) 7.80 (1.46)
Treatment 7.78 (1.09) 6.91 (1.37)a 7.58 (1.11) 7.54 (1.17)a 7.59 (1.13) 7.09 (1.98)a 8.40 (1.68) 7.72 (1.61)
RM-ANOVA P (group);  
P (time); P (interaction)
0.83; <0.001; 0.08 0.76; 0.002; 0.035
Data are presented as mean (SD). Two-way RM-ANOVA was performed to compare the following 4 groups of hearts from healthy (h) and from fructose-fed (ff) rats, 
namely noINS, INS, INS/DIPR, and INS/IL. It was followed by multiple comparison procedures (Holm-Sidak method).
HR = heart rate; CO = cardiac output; LVW = left ventricular work; RM-ANOVA = repeated-measures analysis of variance; noINS = control group (time-matched 
perfusion without insulin; n = 7); INS = insulin-only group (n = 9); INS/DIPR = insulin plus Diprivan (10 μM; n = 7); INS\IL = insulin plus Intralipid (n = 7).
aSignificantly different from corresponding baseline value.
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and Intralipid treatment in diabetic hearts (Fig. 3, C and D). 
Diprivan and Intralipid treatment further activated ERK1/2 
exclusively in diabetic hearts (Fig. 4A). Only Diprivan acti-
vated p38MAPK and S6K1 in diabetic hearts (Fig. 4, B and 
C). Expression of JNK was increased in diabetic hearts 
(Panel C in Supplemental Digital Content 3, http://links.
lww.com/AA/B34), but there was no difference in phos-
phorylation in response to Diprivan or Intralipid treat-
ment (Fig. 4D). Membrane and total tissue expression of 
the novel PKCθ was increased in diabetic hearts (Panel D 
in Supplemental Digital Content 3, http://links.lww.com/
AA/B34). Only Diprivan significantly increased PKCθ 
translocation to the membrane in healthy hearts (Fig. 5A). 
The conventional PKCβII was activated only in Diprivan-
treated healthy and diabetic hearts (Fig. 5B). PKC activation 
by Diprivan only clearly indicates a propofol-specific effect. 
There was no increase in total expression of Akt, GSK3β, 
AMPK, ERK1/2, p38MAPK, S6K1, and PKCβII in diabetic 
hearts compared with healthy hearts (data not shown). 
Likewise, there was no change in phosphorylation of Akt, 
GSK3β, AMPK, ERK1/2, p38MAPK, and S6K1.
Diprivan and Intralipid Promote Accumulation 
of Potentially Diabetogenic Fatty Acid 
Intermediates in Insulin-Stimulated Type-2 
Diabetic Hearts
To determine whether diabetic hearts exposed to Diprivan 
or Intralipid showed changes in concentrations of poten-
tially toxic lipid species, we examined the concentrations of 
phospholipids and sphingolipids in cardiac tissue extracts 
using mass spectrometry. These measurements showed 
accumulation of the phospholipids phosphatidylglycerol 
and phosphatidylethanolamine in Diprivan-treated and 
Intralipid-treated diabetic hearts (Table  3). Unexpectedly, 
only Diprivan but not Intralipid reduced ceramide levels 
in diabetic hearts. In healthy hearts, both Diprivan and 
Intralipid reduced phosphatidylethanolamine, the most 
abundant sphingoid base C18-sphingosine, and its saturated 
counterpart C18-sphinganine (Table 3). Diprivan was more 
effective than Intralipid in increasing C18-sphingosines and 
sphingadienes in diabetic hearts.
DISCUSSION
Fatty acids and fat emulsions impair glucose metabolism 
via the Randle cycle28 and hence are used in experimental 
settings to generate insulin resistance. In otherwise healthy 
volunteers, infusion of long-chain triglycerides reduces 
insulin sensitivity.29 Nonetheless, fat emulsions are widely 
used in surgical patients either as a solvent for the IV anes-
thetic, propofol, or in vulnerable intensive care unit patients 
for sedation or parenteral nutrition. However, not much is 
known as to how fat emulsions or propofol itself affects glu-
cose metabolism in the heart. In our experiments, we used 
type-2 diabetic hearts to establish the impact of propofol 
(Diprivan) and its solvent, Intralipid, on insulin-induced 
glucose uptake. Consistent with previous reports,30 we show 
that the early diabetic heart already exhibits accumulation 
of triglycerides, dysfunctional β-oxidation, and reduced 
oxidative capacity. Our discovery that Intralipid and pro-
pofol in the formulation of Diprivan worsen lipid overload 
Figure 2. GLUT4 trafficking and insulin receptor substrate-1 (IRS-1) phosphorylation in insulin-stimulated healthy and diabetic hearts. A, 
GLUT4 in membrane fractions. GLUT4 levels were normalized to Na+/K+-ATPase. B–D, IRS-1 phosphorylation at Ser1100, Ser307, and Tyr608. 
INS = insulin alone; INS/DIPR = perfusion with insulin and treated with Diprivan (10 μM); INS/IL = perfusion with insulin and treated with 
Intralipid (25 μM); h = healthy; ff = fructose-fed; ANOVA = analysis of variance. N = 4–5 for each group. *Versus INS. #Versus INS/IL.
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and further impair glucose metabolism in these hearts is 
novel but in line with current knowledge on lipotoxicity 
and associated inflammation in the diabetic heart.1,31–33
Our study shows the following salient findings. 
First, insulin-stimulated glucose uptake was reduced in 
Diprivan-treated healthy hearts, and the reduction in glu-
cose uptake under Intralipid treatment almost reached 
statistical significance (P = 0.078). However, only Diprivan 
abolished the action of insulin on glycolytic flux. This was 
accompanied by impaired GLUT4 trafficking to the sarco-
lemma. Conversely, healthy hearts responded to insulin 
in the presence of Intralipid and increased glycolytic flux, 
implying that Intralipid alone only marginally affects insu-
lin sensitivity.28 Possibly, the release of intracellular glucose 
stores from glycogen due to unsaturated fatty acid–induced 
activation of glycogen phosphorylase34 caused the reduc-
tion in glucose uptake without changing GLUT4 trafficking. 
Glycerol, another constituent of Intralipid, may have further 
contributed to pyruvate formation and thus reduced glu-
cose uptake.35 Together, these results indicate that propofol 
itself acutely promotes insulin resistance in healthy hearts. 
This conclusion is also supported by our observation that 
Diprivan, but not Intralipid, caused marked activation and 
membrane translocation of PKCθ and PKCβII as well as the 
phosphorylation at Ser1100(h1101) of the IRS protein IRS-1, 
a key player in insulin signaling.36,37 More recently, insulin 
resistance and feedback inhibition of insulin signaling were 
found to be mediated by serine/threonine phosphorylation 
of IRS-1.36,37 There are as many as 50 serine phosphorylation 
sites of IRS-1 and most of them negatively modulate insulin 
effects, whereas multiple (so far at least 8) tyrosine phosphor-
ylation sites of IRS-1 have opposite effects.37 Ser1100(h1101) 
of IRS-1 is a target of PKCθ,38 the importance of which in 
insulin signaling is further supported by studies showing 
the lack of insulin resistance to dietary challenge in PKCθ-
knockout mice.39,40 Overexpression of PKCβII in mouse skel-
etal muscle induces insulin resistance.41 Both PKC isoforms 
further inhibit insulin receptor tyrosine kinase by serine 
phosphorylation.42 Interestingly, healthy hearts exposed to 
Diprivan showed increased Akt phosphorylation at Ser473 
and Thr308, consistent with full Akt activation. It appears 
that Akt signaling in Diprivan-treated healthy hearts is dys-
functional. However, it inhibits phosphatases,43 and it has 
been reported that sustained phosphorylation of Akt medi-
ates insulin-induced feedback inhibition44 and thus contrib-
utes to cardiac insulin resistance.45
Second, both Diprivan and Intralipid abolished the 
action of insulin on glycolytic flux in early diabetic hearts 
and impaired GLUT4 trafficking to the sarcolemma. In 
addition, Diprivan decreased phosphofructokinase-1 activ-
ity in these hearts. The reduced insulin sensitivity in dia-
betic hearts exposed to Diprivan and Intralipid was closely 
linked to increased phosphorylation of AMPK and stress 
kinases (ERK1/2 and p38MAPK). Insulin inhibits cardiac 
AMPK, and hearts perfused in the absence of insulin have 
been reported to show higher AMPK phosphorylation than 
hearts perfused in the presence of insulin.46 In fact, phosphor-
ylation of AMPK at Ser485 or Ser491 is responsible for the 
Figure 3. Activation pattern of metabolic kinases in insulin-stimulated healthy and diabetic hearts. A, Akt phosphorylation at Ser473. B, Akt 
phosphorylation at Thr308. C, GSK3β phosphorylation at Ser9. D, AMPK phosphorylation at Thr172. INS = insulin alone; INS/DIPR = perfusion 
with insulin and treated with Diprivan (10 μM); INS/IL = perfusion with insulin and treated with Intralipid (25 μM); h = healthy; ff = fructose-fed; 
ANOVA = analysis of variance. N = 4–5 for each group. *Versus INS. #Versus INS/IL.
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effect of high insulin concentrations to blunt AMPK activa-
tion (Thr172 site) in the heart.47 Our data are thus consistent 
with the concept that activation of AMPK ensures adequate 
cardiac energy production when glucose utilization is com-
promised.48 AMPK also inhibits insulin signalling by phos-
phorylating IRS-1 at Ser789(h794).49 Diprivan-mediated and 
Intralipid-mediated insulin resistance and AMPK activation 
may have also lead to the observed accumulation of gly-
cogen in diabetic hearts.50 Consistent with this interpreta-
tion, glycogen synthase kinase-3β phosphorylation was 
increased in Diprivan-treated and Intralipid-treated dia-
betic hearts leading to the activation of glycogen synthase. 
Finally, increased ERK1/2 and p38MAPK activities also 
inhibit IRS-1 by phosphorylation at Ser612 (ERK1/2)37,51 
and Ser636 (p38MAPK),52 respectively. In diabetic hearts, 
only Diprivan treatment activated PKCβII and the pro-
inflammatory S6K1, which also promotes Ser1100(h1101) 
phosphorylation of IRS-1,53 again implying distinct diabeto-
genic effects of propofol itself.
Third, our study shows for the first time that admin-
istration of Diprivan and Intralipid leads to accumula-
tion of potentially diabetogenic lipids in the heart. A 
recent study found that prediabetes and type-2 diabetes 
are associated with increased plasma levels of phospha-
tidylethanolamine, phosphatidylglycerol, and cerami-
des.54 Lysophosphatidylcholine, another phospholipid, is 
reportedly an efficient effector of fatty acid–induced insu-
lin resistance.55 Lysophosphatidylcholine activates JNK, 
which phosphorylates IRS-1 at Ser307(h312). Moreover, the 
increased levels of phosphatidylethanolamine detected in 
Figure 4. Activation pattern of stress kinases in insulin-stimulated healthy and diabetic hearts. A, ERK1/2 phosphorylation at Thr202/Tyr204. 
B, p38MAPK phosphorylation at Thr180/Tyr182. C, S6K1 phosphorylation at Thr389. D, JNK phosphorylation at Thr183/Tyr185. INS = insulin 
alone; INS/DIPR = perfusion with insulin and treated with Diprivan (10 μM); INS/IL = perfusion with insulin and treated with Intralipid (25 μM); 
h = healthy; ff = fructose-fed; ANOVA = analysis of variance. N = 4–5 for each group. *Versus INS. #Versus INS/IL.
Figure 5. Protein kinase C (PKC) activation in insulin-stimulated 
healthy and diabetic hearts. A, Translocation of novel PKCθ as mea-
sured by membrane-to-cytosolic ratio. B, Conventional PKCβII pro-
tein levels in the membrane fraction. INS = insulin alone; INS/DIPR 
= perfusion with insulin and treated with Diprivan (10 μM); INS/
IL = perfusion with insulin and treated with Intralipid (25 μM); h = 
healthy; ff = fructose-fed; ANOVA = analysis of variance. N = 4–5 for 
each group. *Versus INS. #Versus INS/IL.
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Table 3.  Phospholipids and Sphingolipids in Perfused Healthy and Diabetic Hearts
h-INS h-INS/DIPR h-INS/IL ff-INS ff-INS/DIPR ff-INS/IL
Phospholipids
  Phosphatidylethanolamine (nmol•mg−1) 60 (11) 45 (6)a 46 (8)a 48 (11) 71 (14)a 65 (13)a
  P 0.015 0.009
  Lysophosphatidylcholine (nmol•mg−1) 68 (32) 84 (34) 67 (25) 108 (43) 143 (49) 120 (29)
  P 0.524 0.308
  Lysophosphatidylethanolamine (nmol•mg−1) 89 (68) 53 (31) 47 (21) 62 (29) 75 (30) 102 (41)
  P 0.213 0.106
  Phosphatidylglycerol (nmol•mg−1) 4.0 (1.1) 4.0 (2.1) 3.1 (2.4) 3.1 (0.6) 4.5 (1.0)a 4.5 (1.4)a
  P 0.674 0.025
  Sphingomyelin (nmol•mg−1) 38 (8) 29 (5) 31 (11) 25 (5) 29 (6) 28 (5)
  P 0.140 0.262
  Ceramides (nmol•mg−1) 1.4 (0.4; 2.7) 2.2 (0.7; 4.5) NA 4.1 (2.2) 1.3 (1.3)b 4.4 (1.9)
  P NA 0.021
Sphingoid bases
  C16SO (pmol per 100 μg) 0.7 (0.1) 0.8 (0.1) 0.7 (0.1) 0.6 (0.1) 0.6 (0.1) 0.5 (0.1)
  P 0.209 0.05
  C17SO (pmol per 100 μg) 2.3 (0.2) 2.0 (0.2) 2.0 (0.3) 1.4 (0.2) 1.6 (0.3) 1.6 (0.4)
  P 0.072 0.544
  C18SO (pmol per 100 μg) 162 (13) 123 (12)a 134 (17)a 109 (10) 148 (17)ab 132 (14)a
  P <0.001 <0.001
  C18SA-diene (pmol per 100 μg) 41 (5) 38 (5) 36 (4) 29 (5) 47 (10)a 38 (7)a
  P 0.137 0.001
  C18SA (pmol per 100 μg) 2.4 (0.4) 1.5 (0.2)a,b 1.9 (0.2)a 1.4 (0.2) 1.6 (0.3) 1.4 (0.2)
  P <0.001 0.338
  C20SO (pmol per 100 μg) 0.3 (0.06) 0.5 (0.1)b 0.3 (0.06) 0.4 (0.1) 0.3 (0.05) 0.3 (0.1)
  P <0.001 0.299
Data are presented as mean (SD) or median (25th, 75th percentile). Analysis of variance was performed to compare INS, INS/DIPR, and INS/IL from healthy (h) 
and from fructose-fed (ff) rats. It was followed by a multiple comparison procedure (Holm-Sidak method). C16-sphinganine and the saturated and unsaturated 
deoxy-sphingoid bases were not detectable. N = 7 in all groups. Differences are considered significant (boldface) if the overall P < 0.05. 
INS = insulin-only group; INS/DIPR = insulin plus Diprivan (10 μM); INS\IL = insulin plus Intralipid (25 μM); C16SO = C16-sphingosine (d16:1); C17SO = C17-
sphingosine (d17:1); C18SO = C18-sphingosine (d18:1); C20SO = C20-sphingosine (d20:1); C18SA = C18-sphinganine (d18:0); C18SA-diene = sphingadiene 
(d18:2); NA = not available.
aSignificantly different from INS.
bSignificantly different from INS and INS/IL.
Figure 6. Working model of lipotoxicity by Diprivan and Intralipid in the heart. The diabetic heart is overloaded by fatty acid species and 
exhibits dysfunctional β-oxidation. Provision of supplementary fat or propofol to the diabetic myocardium raises levels of toxic lipids, which 
activate kinases mediating insulin resistance by hyperphosphorylation of the insulin receptor substrate-1 (IRS-1) at multiple serine/threonine 
residues. The hyperphosphorylated state of the IRS-1 reduces the activity of the insulin receptor (IR) tyrosine kinase and of phosphoinositide 
3-kinase (PI3K). Reduced tyrosine kinase activity of the IR inhibits GLUT4 translocation via the Casitas b-lineage lymphoma (c-Cbl)-TC10 (a 
small GTPase) pathway (PI3K-independent), while reduced PI3K activity also reduces GLUT4 translocation. In contrast to conventional and 
novel PKC, atypical PKC promote GLUT4 trafficking. In healthy hearts, propofol persistently increases Akt activity possibly by inhibiting PP2A 
phosphatase activity,43 which also provides feedback inhibition to the IRS-1 and reduces GLUT4 trafficking.
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our study in the diabetic myocardium exposed to Diprivan 
and Intralipid may exert strong proinflammatory effects 
when oxidized or glycated.56 Recent studies also linked 
increased plasma sphingolipid levels to impaired insulin 
signaling.22
Taken together, our data suggest that propofol and 
Intralipid activate key kinases involved in serine/threo-
nine phosphorylation of IRS-1 and thereby reduce insulin 
signaling (Fig. 6). Increased serine phosphorylation of IRS-1 
reduces GLUT4 trafficking either downstream via reduced 
phosphoinositide 3-kinase activation45,57,58 or upstream 
via inhibition of insulin receptor tyrosine kinase activ-
ity,59 which initiates small GTPase (TC10)–mediated phos-
phoinositide 3-kinase–independent GLUT4 exocytosis.57
Because insulin resistance is tightly associated with 
increased morbidity and mortality,4–6 it is possible that 
further impairment of insulin signaling by Diprivan or 
Intralipid treatment in at-risk patients with diabetes may 
worsen clinical outcomes. A meta-analysis in surgical and 
critically ill patients reported higher complication rates in 
subgroups of patients treated with lipid-based parenteral 
nutrition compared with patients receiving lipid-free for-
mulations.60 Hence, future studies in at-risk patients are 
necessary to address the relevance of our experimental 
observations in the clinical setting.
In conclusion, our experiments show that Diprivan 
and Intralipid reduce glucose uptake predominantly in 
diabetic hearts. The loss of metabolic flexibility is trig-
gered by alterations in insulin signaling and GLUT4 traf-
ficking and accompanied by accumulation of potentially 
diabetogenic lipids.
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